Literature DB >> 20238294

Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma.

Daniela Segat1, Mauro Cassaro, Emanuela Dazzo, Lucia Cavallini, Chiara Romualdi, Renato Salvador, Maria Pia Vitale, Libero Vitiello, Matteo Fassan, Massimo Rugge, Giovanni Zaninotto, Ermanno Ancona, Maurizio David Baroni.   

Abstract

Barrett's esophagus metaplasia is a pre-cancerous condition caused by chronic esophagitis. Chromosomal instability (CIN) is common in Barrett's cells: therefore, we investigated the possible presence of centrosomal aberrations (a main cause of CIN) by centrosomal protein immunostaining in paraffined esophageal samples of patients who developed a Barrett's adenocarcinoma. In most (55%) patients, alterations of the pericentriolar material (PCM) signals were evident and consistently marked the transition between normal epithelium to metaplasia. The alterations could even be found in adjacent native squamous epithelium, Barrett's mucosa and submucosal gland cells, as well as in the basal/epibasal layers of the mucosa and submucosal gland duct, which are the regions hosting esophageal stem and progenitor cells. These findings strongly support the hypothesis that the three esophageal histotypes (one being pathological) can have a common progenitor. Surprisingly, PCM defective signal eventually decreased with neoplastic progression, possibly to enhance the genome stability of advanced cancer cells. Importantly, PCM altered signals in Barrett's mucosa and their apparent evolution in successive histopathological steps were correlated to adenocarcinoma aggressiveness, suggesting PCM as a possible prognostic marker for tumor relapse. Extending our observations in a prospective study might help in the development of new prevention protocols for adenocarcinoma patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20238294     DOI: 10.14670/HH-25.551

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  8 in total

Review 1.  How to be good at being bad: centrosome amplification and mitotic propensity drive intratumoral heterogeneity.

Authors:  Padmashree C G Rida; Guilherme Cantuaria; Michelle D Reid; Omer Kucuk; Ritu Aneja
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

Review 2.  Causes and consequences of centrosome abnormalities in cancer.

Authors:  S A Godinho; D Pellman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-09-05       Impact factor: 6.237

Review 3.  A clinical overview of centrosome amplification in human cancers.

Authors:  Jason Yongsheng Chan
Journal:  Int J Biol Sci       Date:  2011-10-16       Impact factor: 6.580

4.  Asymmetric clustering of centrosomes defines the early evolution of tetraploid cells.

Authors:  Nicolaas C Baudoin; Joshua M Nicholson; Kimberly Soto; Olga Martin; Jing Chen; Daniela Cimini
Journal:  Elife       Date:  2020-04-29       Impact factor: 8.140

Review 5.  An updated view on the centrosome as a cell cycle regulator.

Authors:  Muyang Lin; Shuang Shuang Xie; Kuan Yoow Chan
Journal:  Cell Div       Date:  2022-02-14       Impact factor: 5.130

Review 6.  Moonlighting at the Poles: Non-Canonical Functions of Centrosomes.

Authors:  Laurence Langlois-Lemay; Damien D'Amours
Journal:  Front Cell Dev Biol       Date:  2022-07-14

7.  Structural centrosome aberrations favor proliferation by abrogating microtubule-dependent tissue integrity of breast epithelial mammospheres.

Authors:  D Schnerch; E A Nigg
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

8.  Over-expression of Plk4 induces centrosome amplification, loss of primary cilia and associated tissue hyperplasia in the mouse.

Authors:  Paula A Coelho; Leah Bury; Marta N Shahbazi; Kifayathullah Liakath-Ali; Peri H Tate; Sam Wormald; Christopher J Hindley; Meritxell Huch; Joy Archer; William C Skarnes; Magdalena Zernicka-Goetz; David M Glover
Journal:  Open Biol       Date:  2015-12       Impact factor: 6.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.